Compounded versus brand GLP-1s, without the marketing
A compounded GLP-1 is not a generic. Nobody checked it for safety, effectiveness or quality before it went on sale — that is what “not FDA approved” means, and the FDA says so in those words. What it is instead is a drug a licensed pharmacy made to order, under rules that changed sharply once semaglutide and tirzepatide came off the shortage list.
Evidence read September 2026. Nobody here holds a medical license and none of this is medical advice. Every source below is listed so you can check it yourself.What this comes down to
- Compounded drugs are not FDA approved. The agency does not review them for safety, effectiveness or quality before they are marketed.
- Neither semaglutide injection nor tirzepatide injection appears on the FDA's current shortage list. Liraglutide, another GLP-1, does — so the list still carries this drug class.
- Two kinds of compounder exist and they are held to different standards. Outsourcing facilities are subject to manufacturing regulations; state-licensed 503A pharmacies are not.
- As of May 31, 2026 the FDA had 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and says both are likely undercounted.
It is not a generic, and the difference is legal not semantic
A generic drug is approved under a specific section of federal law and has to establish therapeutic equivalence to the brand. A compounded drug is approved under nothing. The FDA puts it plainly: compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed[1]. Consumers and clinicians rely on the approval process for exactly that verification, and compounding sits outside it by design. The approved products in this class are few and named: semaglutide as Ozempic, Wegovy and Rybelsus, and tirzepatide as Zepbound, approved in November 2023[4].
That design has a purpose. Compounding exists for the patient who can't use the approved product — an allergy to a dye, a child who can't swallow a tablet, a dose the manufacturer doesn't make. The agency's own framing is that compounded drugs should only be used when an approved drug can't meet the medical need[2].
The shortage window, and what closed it
Federal law lets compounders prepare a version of a drug that is on the FDA's shortage list, if certain conditions are met[1]. That is the door most compounded GLP-1s came through, and it is the door that closed. We read the FDA's shortage database directly[3]: the current table holds 74 entries, 70 of them currently in shortage. Semaglutide injection is not among them and neither is tirzepatide injection. Liraglutide injection is — so the absence is not the database failing to carry GLP-1s.
FDA Drug Shortages database, the Current and Resolved shortages table
Full read of the rendered table, matching on active ingredient
Returned 0. Positive control — liraglutide injection, same table, same read — returned 1 through the identical filter in the same session. Read September 2026.
The table held 74 rows: 70 currently in shortage and 4 resolved. Semaglutide appears only as an oral tablet under discontinuations. ⚠ The database's per-ingredient detail pages could not be used — they return an identical empty shell for a real ingredient and a nonexistent one alike, so the rendered index is the only readable form.
With the shortage route gone, a lot of compounding now runs on the argument that a specific patient needs a dose or a combination the approved product does not offer. Whether any given prescription genuinely meets that bar is a question about that prescription, not about the category. What it is not is a shortage exemption, and a company still describing its product as available because of a shortage is describing 2024.
Two kinds of compounder, two sets of rules
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Primary oversight | State board of pharmacy, day to day | The FDA, on a risk-based inspection schedule |
| Manufacturing regulations | Not subject to current good manufacturing practice | Subject to current good manufacturing practice |
| Makes drugs | For an identified patient, on a prescription | In batches, with or without patient-specific prescriptions |
| FDA approval of the product | None | None |
Read from the FDA's compounding questions and answers, September 2025.
Both are legal. Neither product is approved. The gap between them is quality systems, and it is the reason “which pharmacy compounds this” is the most useful question a buyer can ask a telehealth company. Most of the sellers we grade name one; our reviews record what each said, and what it declined to say.
What actually goes wrong
The FDA keeps a running account of it, and the failures are specific rather than theoretical[2]. Dosing errors, some requiring hospitalization, from patients and clinicians miscalculating a dose out of a multi-dose vial. Products dispensed in vials holding several doses, which the agency says should be discarded 28 days after first use regardless of what the compounder's own instructions say. Shipments arriving warm or with inadequate ice. Salt forms — semaglutide sodium, semaglutide acetate — which are different active ingredients from the approved drug and for which the FDA says it is not aware of any lawful basis for use in compounding.
And then the outright fakes. The agency says it is aware of fraudulent compounded semaglutide and tirzepatide carrying false label information, including labels naming compounding pharmacies that do not exist, and labels naming a real licensed pharmacy that did not make the product[2].
The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of any approved drug, and have not been found safe and effective for anything. It has warned telehealth companies for marketing them, distributors for selling them to compounders, and outsourcing facilities for repackaging them. A company offering retatrutide is not offering an early look at a promising drug.
Where the price actually lands
Compounded is usually cheaper, and that is most of why the market exists. It is also where the headline pricing games are worst: 21 of the 74 priced plans we have checked, across 13 of 28 sellers, advertise a lower monthly figure than the one that actually recurs. What “starting at” is really buying you takes that apart. Every figure behind it is sourced under how we verify prices.
Questions people actually ask
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It contains semaglutide, but it is a different product made by a different party under different rules, and it has not been reviewed by the FDA for safety, effectiveness or quality. A generic has to prove equivalence to the brand; a compounded drug never makes that comparison.
Is compounded semaglutide still legal now that the shortage ended?
Compounding itself remains legal, but the shortage route that most of this market used is gone — semaglutide injection is not on the FDA's current shortage list. What remains are the ordinary grounds for compounding, which turn on an individual patient's needs rather than on supply.
How can I tell who actually made my medication?
Read the label and look for the compounding pharmacy's name, then check that pharmacy exists and is licensed. The FDA has warned about labels naming pharmacies that do not exist and labels naming real pharmacies that did not make the product.
Should I throw away a multi-dose vial after 28 days?
The FDA recommends discarding a multi-dose vial of sterile medication 28 days after first use even if medication remains, and says not to keep using it past that point even if the compounder's instructions allow longer.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it.
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025; read September 2026Compounded drugs are not FDA approved and the agency does not verify safety, effectiveness or quality before marketing; a generic is approved under section 505(j) and must establish therapeutic equivalence; compounders may prepare versions of drugs on the FDA shortage list under conditions in federal law; outsourcing facilities are subject to current good manufacturing practice and 503A pharmacies are not; state boards have primary day-to-day oversight of 503A pharmacies.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026; read September 2026As of May 31, 2026 the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and notes these are likely underreported; retatrutide and cagrilintide cannot be used in compounding under federal law; the agency recommends discarding multi-dose vials 28 days after first use; semaglutide salt forms are different active ingredients with no lawful basis the agency is aware of for use in compounding; fraudulent compounded products have carried labels naming pharmacies that do not exist.
- FDA Drug Shortages database. U.S. Food and Drug Administration, 2026. Source · Read September 2026The Current and Resolved shortages table held 74 entries on the day it was read, 70 currently in shortage; liraglutide injection was among them and neither semaglutide injection nor tirzepatide injection appeared.
- Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. Source · Read September 2026Zepbound (tirzepatide, NDA 217806) was approved November 8, 2023; semaglutide is approved as Ozempic, Wegovy and Rybelsus under separate applications held by Novo Nordisk.
Read next
- What “starting at” is really buying you — The mechanics behind every headline price in this market.
- How a telehealth prescription actually happens — Who writes it, what they see, and the FDA's own red-flag list.
- How we grade a seller — Five letters, one standard, written before the money is checked.